Artios Pharma CEO Niall Martin was featured in InVivo’s piece on “Biotech CEOs: Entrepreneurs who want to translate their ideas into companies”.
Artios is on a mission to put DNA repair on the map. Niall Martin talked to Labiotech about his experiences as CEO and explained why it’s important to plan ahead, protect your technology and not to sell out too short or too soon. Putting DNA Repair on the Map
Artios is attacking a different DNA Damage Response pathway that could be more selective than PARP inhibitors.
Proactive Investors’ Andrew Scott sits down with Arix Bioscience Plc’s (LON:ARIX) investment director Jonathan Tobin and Niall Martin, chief executive of Artios Pharma to discuss the Series B financing. https://www.proactiveinvestors.co.uk/companies/stocktube/10188/artios-in-strong-position-to-accelerate-cancer-programmes-after-arix-investment-10188.html
With DNA damage repair pathways attracting a lot of attention as potential targets against various cancers, three-year old Artios Pharma has raised £65 million in an over-subscribed Series B round to fund the clinical development of its pipeline through to 2023. https://scrip.pharmaintelligence.informa.com/SC123568/Artios-Pharma-Hooks-Novartis–Pfizer-In-OverSubscribed-65M-Series-B-Round
LSX article on Artios following our recent £65 million Series B fundraise and having being shortlisted in the EU Private Finance Raise of the Year (>£30m) category and also the EU Private Company of the Year category at this year’s Lifestars Awards 2018. This follows a double win at LSX’s Biotech and Money Awards 2017. […]
Artios Pharma scooped two awards at the Biotech and Money Awards 2017. The DNA Damage Response company was named winner in the UK Life Science Young Company of the Year (1-3 years old) category and the UK Private Finance Raise of the Year (≤£25 million) category. Biotech and Money spoke to Artios Pharma’s Chief Executive […]